Yesterday Teva reported Q2 2025 results, highlighted by a re-acceleration in Uzedy sales to USD54m (+24% vs css), with Teva raising the product's sales guidance to USD190-200m for FY25 from USD160m. TRx data continues to support the product's growth (3x TRx YoY), with Teva reporting >80% NBRx fr
1H25 results were softer than expected with group GTV remaining flat at € 9.4bn (css: € 9.5bn) driven by a 7% decline in orders to € 308m (css: € 314m). Excluding the RoW, GTV growth at CCY of 2% was broadly in line. Revenues decreased 1% at ccy to € 1747m (kbcse: € 1771m), with lower order volumes partially offset by improved monetization and higher advertising revenues. Adj. EBITDA growth of 4% to € 147m came in below expectations (css: € 167m), driven by logistics investments and marketing in...
Aedifica: Strong results, guidance reiterated; dsm-firmenich: Symrise 1H25 results; IMCD: Stagnating gross profit leads to disappointing 2Q25 EBITA; JDE Peet's: Full of beans; Just Eat Takeaway: 1H25 results, weak update no impact on takeover; Lotus Bakeries: Peer Mondelez 1Q25 results; Melexis: 2Q25 results, gross margin under pressure; Solvay: 2Q25 in line, subdued outlook no surprise after pre-release; TKH Group: Preview: Under a magnifying glass; Universal Music Group: Spotify 2Q25 ...
We downgrade our rating from Buy to HOLD and lower our target price to €6 per share (from €9). We believe the company's growth profile has become more uncertain, and less attractive in our view. We still view CM.com's one-stop-shop as unique and still forecast gross profit growth of 10% by 2028, but we believe the path forward will be more gradual. For us to become more positive on the case, we would need to see more material growth impact from non-Connect business units (Engage, Pay, Live), and...
ASM International: 2Q25 Results; Positive tone, weak orders. CM.com: 1H25 results; disappointing performance, guidance downgrade. Gimv: Gimv fuels Hemink's sustainable expansion. KPN: Solid 2Q25, guidance raised largely on €25m IPR claim benefit. Philips: 2Q25 Preview; improvement needed. Randstad: 2Q25 in line; outlook touch below; FX spoils the party but operational leverage story is unfolding. Sofina: Newsletter #16. Universal Music Group: EU opens in-depth investigation into Downtown ...
Akzo Nobel: FX drives 2Q25 miss and FY guidance cut. dsm-firmenich: Givaudan 1H25 results. Exor: In talks over Iveco sale. Lotus Bakeries: Peer Lindt & Sprüngli 1H25 results. Proximus: CpaaS peer Sinch 2Q25 results hurt by FX. Signify: 2Q25 Preview, challenges ahead. Var Energi: Promising continuation of dividend. Vopak: Continued story. Wereldhave: Strong operational results, positive market tone, guidance raised. Events Calendar
TomTom reported a largely in line 2Q25 update and skewed an, in our view, initially conservative guidance to the upside. We have a mixed view on the investment case. We believe the platform improved a lot in both quality and efficiency with the move to Orbis but we need to see more significant growth for operational leverage to kick in. We adjust our estimates, offsetting lower growth with improved platform efficiency. We reiterate our HOLD and €5.0 target price.
ASM: 2Q25 Preview, AI winner BE Semiconductor Industries: 2Q25 Preview, focus on advanced order intake CM.com: Preview 1H25 D'Ieteren: Belron $4.655bn TBL repriced 25bp lower PostNL: Preview 2Q25F; consensus released Wolters Kluwer: To divest Finance, Risk and Regulatory Reporting unit
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.